Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -62.56% is in line with its 5-year average of -62.14%, around the middle of its 5-year range (-126.53%–-19.78%).
As of the fiscal period ended Tuesday, June 30, 2026. 24.59% above its 12-month average of -82.97%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q3 FY2026 (2026-06-30): -62.56%.
RETURN ON EQUITY (ROE)
-62.56%
RETURN ON EQUITY (ROE) AVG TTM
-82.97%
RETURN ON EQUITY (ROE) AVG 3Y
-80.61%
RETURN ON EQUITY (ROE) AVG 5Y
-62.14%
RETURN ON EQUITY (ROE) AVG 10Y
-29.08%
RETURN ON EQUITY (ROE) AVG 15Y
-13.03%
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+24.59%
CURRENT VS 3Y AVG
+22.39%
CURRENT VS 5Y AVG
-0.67%
CURRENT VS 10Y AVG
-115.14%
CURRENT VS 15Y AVG
-380.27%
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-40.21%
median of 529 covered companies
CURRENT VS SECTOR MEDIAN
-55.59%
vs the sector median at left
Enanta Pharmaceuticals, Inc.
Market Cap
$349.23M
Return on Equity (ROE)
-62.56%
TTM Avg
-82.97%
3Y Avg
-80.61%
5Y Avg
-62.14%
Market Cap
$347.70M
Return on Equity (ROE)
N/A
TTM Avg
-589.37%
3Y Avg
-290.01%
5Y Avg
-205.39%
Market Cap
$354.19M
Return on Equity (ROE)
N/A
TTM Avg
-12.63%
3Y Avg
-14.73%
5Y Avg
14.28%
Market Cap
$354.37M
Return on Equity (ROE)
N/A
TTM Avg
187.63%
3Y Avg
25.60%
5Y Avg
-9.96%
Market Cap
$352.93M
Return on Equity (ROE)
-7.66%
TTM Avg
-10.18%
3Y Avg
260.20%
5Y Avg
144.75%
Market Cap
$341.47M
Return on Equity (ROE)
-26.14%
TTM Avg
-53.80%
3Y Avg
-12.25%
5Y Avg
19.21%
Market Cap
$355.99M
Return on Equity (ROE)
-200.64%
TTM Avg
-134.16%
3Y Avg
-101.12%
5Y Avg
-54.69%
Market Cap
$332.73M
Return on Equity (ROE)
-320.77%
TTM Avg
-82.83%
3Y Avg
-78.63%
5Y Avg
-104.90%
Market Cap
$334.29M
Return on Equity (ROE)
N/A
TTM Avg
34.79%
3Y Avg
145.50%
5Y Avg
100.23%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Enanta Pharmaceuticals, Inc. (ENTA) | $349.23M | -62.56% | -82.97% | -80.61% | -62.14% |
| Opus Genetics, Inc. (IRD)vs › | $347.70M | N/A | -589.37% | -290.01% | -205.39% |
| Embecta Corp. (EMBC)vs › | $354.19M | N/A | -12.63% | -14.73% | 14.28% |
| Ocugen, Inc. (OCGN)vs › | $354.37M | N/A | 187.63% | 25.60% | -9.96% |
| Fennec Pharmaceuticals Inc. (FENC)vs › | $352.93M | -7.66% | -10.18% | 260.20% | 144.75% |
| Artiva Biotherapeutics, Inc. (ARTV)vs › | $341.47M | -26.14% | -53.80% | -12.25% | 19.21% |
| Orchestra BioMed Holdings, Inc. (OBIO)vs › | $355.99M | -200.64% | -134.16% | -101.12% | -54.69% |
| ClearPoint Neuro, Inc. (CLPT)vs › | $332.73M | -320.77% | -82.83% | -78.63% | -104.90% |
| Agenus Inc. (AGEN)vs › | $334.29M | N/A | 34.79% | 145.50% | 100.23% |
| Canopy Growth Corporation (CGC)vs › | $370.48M | -38.57% | -80.22% | -181.01% | -130.47% |
ROE
-62.6%
ROA
-21.3%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -62.56% |
| 2026-03-31 | -53.17% |
| 2025-12-31 | -56.51% |
| 2025-09-30 | -126.53% |
| 2025-06-30 | -116.06% |
| 2025-03-31 | -103.08% |
| 2024-12-31 | -93.84% |
| 2024-09-30 | -90.09% |
| 2024-06-30 | -77.45% |
| 2024-03-31 | -79.30% |
| 2023-12-31 | -72.04% |
| 2023-09-30 | -61.74% |
| 2023-06-30 | -55.53% |
| 2023-03-31 | -46.29% |
| 2022-12-31 | -40.10% |
| 2022-09-30 | -37.89% |
| 2022-06-30 | -35.50% |
| 2022-03-31 | -31.33% |
| 2021-12-31 | -26.22% |
| 2021-09-30 | -19.78% |
| 2021-06-30 | -20.04% |
| 2021-03-31 | -16.97% |
| 2020-12-31 | -12.82% |
| 2020-09-30 | -7.94% |
| 2020-06-30 | 0.49% |
| 2020-03-31 | 4.87% |
| 2019-12-31 | 7.01% |
| 2019-09-30 | 10.03% |
| 2019-06-30 | 14.42% |
| 2019-03-31 | 17.85% |
| 2018-12-31 | 20.21% |
| 2018-09-30 | 18.28% |
| 2018-06-30 | 22.46% |
| 2018-03-31 | 15.70% |
| 2017-12-31 | 10.83% |
| 2017-09-30 | 5.87% |
| 2017-06-30 | -7.90% |
| 2017-03-31 | -4.98% |
| 2016-12-31 | -3.54% |
| 2016-09-30 | 8.03% |
| 2016-06-30 | 10.88% |
| 2016-03-31 | 12.30% |
| 2015-12-31 | 23.90% |
| 2015-09-30 | 33.45% |
| 2015-06-30 | 29.85% |
| 2015-03-31 | 51.63% |
| 2014-12-31 | 42.24% |
| 2014-09-30 | 23.17% |
| 2014-06-30 | 22.91% |
| 2014-03-31 | -18.83% |
| 2013-12-31 | -16.76% |
| 2013-09-30 | 8.71% |
| 2013-06-30 | 8.76% |
| 2013-03-31 | 9.00% |
| 2012-12-31 | 70.25% |
| 2012-09-30 | 48.71% |
